Dr. Aliyah Pabani, MD

Dr. Pabani practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Pabani's NPI, 1124511092, was assigned on June 14, 2018. Dr. Pabani holds Maryland license D98244.

Dr. Pabani's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Pabani's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Pabani is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Pabani to 1 more hospital, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pabani practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Pabani's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Pabani is licensed in Maryland.

CMS data shows 207 Medicare services from Dr. Pabani across 5 procedure codes in 2024, for 96 Medicare patients. Medicare paid $20,911 for them.

CMS counts 96 Medicare patients who saw Dr. Pabani in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pabani's median patient age at 70, with 38% women.

In 2024, Dr. Pabani wrote 118 Medicare Part D claims for 33 patients. 86% of them were for generic drugs. CMS names the drug for 72 of them, across 4 drugs with 11 or more claims each, at $1,277 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Pabani for performance year 2024, reported as part of a group. CMS lists Dr. Pabani as offering telehealth.

Dmand AI links 26 papers to Dr. Pabani, published from 2018 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Immune Checkpoint Inhibitors. Dr. Pabani has published most often in Curr Oncol. Dr. Pabani's most frequent co-authors are Naiyer A. Rizvi, MD, Sadia Nafees Ahmed, MD and Mark M. Awad, MD, PhD.

Dmand AI links Dr. Pabani to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Lung Neoplasms and Carcinoma, Bronchogenic.

CMS Open Payments shows 14 general payments to Dr. Pabani from 4 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 78% of the total. Partner Therapeutics, Inc. paid the most, $4,407.